INCB123667 Clinical Trials (2026): 6 Studies for Healthy Participants & Ovarian Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
6 INCB123667 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Healthy Participants & Ovarian Cancer) and 718 total planned enrollment. 1 Phase 3 INCB123667 trial and 1 Phase 2 are listed. 5 INCB123667 clinical trials are actively recruiting at 35 U.S. sites across 23 states. Most recent activity: NCT07214779 (May 2029).
Where to Participate: All INCB123667 Trial Sites in the U.S. (35 sites across 23 states)
Every actively recruiting INCB123667trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Usa Health Mitchell Cancer Institute | Mobile36604 | NCT07023627 | Map |
| CA | University of California, Los Angeles Medical Center | Los Angeles90024-6995 | NCT07023627 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT07214779 | Map |
| CA | Scripps Healthscripps Mercy Hospital Prebys Cancer Center | San Diego92103 | NCT07023627 | Map |
| DC | Medstar Georgetown University Hospital | Washington D.C.20010 | NCT07023627 | Map |
| FL | Florida Cancer Specialists & Research Institute | Fort Myers33901 | NCT07023627 | Map |
| FL | Sylvester Comprehensive Cancer Center | Miami33136 | NCT07023627 | Map |
| FL | Mount Sinai Comprehensive Cancer Center | Miami Beach33140 | NCT07023627 | Map |
| FL | Florida Cancer Specialists & Research Institute | West Palm Beach33401 | NCT07023627 | Map |
| GA | Northeast Georgia Medical Center Gainesville | Gainesville30501 | NCT07023627 | Map |
| IN | Parkview Research Center | Fort Wayne46845 | NCT07023627 | Map |
| IA | University of Iowa Hospital and Clinics | Iowa City52242-1009 | NCT07023627 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT07023627 | Map |
| LA | Trials365, Llc | Shreveport71103 | NCT07023627 | Map |
| MD | Greater Baltimore Medical Center | Baltimore21204 | NCT07023627 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07023627 | Map |
| MN | Minnesota Oncology-Minneapolis | Minneapolis55404 | NCT07023627 | Map |
| MO | Washington University | St Louis63110 | NCT07023627 | Map |
| MT | Billings Clinic | Billings59101 | NCT07214779 | Map |
| MT | St. Vincent Regional Hospital - West End Clinic | Billings59106 | NCT07023627 | Map |
| NE | Celerion, Inc | Lincoln68502 | NCT06909162 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT07023627 | Map |
| NJ | John Theurer Cancer Center, Hackensack University Medical Center | Hackensack07601 | NCT07023627 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center | New York10016 | NCT07023627 | Map |
| OH | Oncology Hematology Care, Inc | Cincinnati45242 | NCT07023627 | Map |
| OH | The Mark H Zangmeister Cancer Center Ohio | Columbus43219 | NCT07023627 | Map |
| OH | The Ohio State University Wexner Medical Center Division of Gynecologic Oncology | Hilliard43026 | NCT07023627 | Map |
| TN | Erlanger Health, Inc. | Chattanooga37403 | NCT07214779 | Map |
| TX | Texas Oncology-Austin Center | Austin78731 | NCT07023627 | Map |
| TX | Texas Oncology-San Antonio Medical Center Pharmacy | San Antonio78229 | NCT07023627 | Map |
| TX | Texas Oncology-Tyler | Tyler75702 | NCT07023627 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT07023627 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT07023627 | Map |
| VA | Carilion Clinic | Roanoke24016-4962 | NCT07023627 | Map |
| WV | West Virginia University | Morgantown26506 | NCT07023627 | Map |
INCB123667 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | 2 | 4 |
| P2 | 1 | 1 | ||
| P3 | 1 | 1 |
Recruiting INCB123667 clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07214779 | MAESTRA 2Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | P3 | Ovarian Cancer | 466 | Dec 2025 |
| NCT07023627 | MAESTRA 1A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | P2 | Ovarian Cancer | 160 | Nov 2025 |
| NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | P1 | Hepatic Insufficiency | 16 | May 2026 |
| NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease | P1 | Renal Impairment | 16 | May 2026 |
| NCT06909162 | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants | P1 | Healthy Participants | 51 | May 2025 |
INCB123667 clinical trials by indication
Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07214779 | MAESTRA 2 | P3 | recruiting | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression |
| NCT07023627 | MAESTRA 1 | P2 | recruiting | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression |
Healthy Participants (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06909162 | — | P1 | recruiting | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants |
| NCT07218744 | — | P1 | completed | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants |
Renal Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07559396 | — | P1 | not yet recruiting | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease |
Hepatic Insufficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07559474 | — | P1 | not yet recruiting | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment |
INCB123667 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MAESTRA 2 | NCT07214779 | P3 | recruiting | Ovarian Cancer | 466 | — |
| MAESTRA 1 | NCT07023627 | P2 | recruiting | Ovarian Cancer | 160 | — |
All INCB123667 trials (6)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07214779 | MAESTRA 2 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | P3 | recruiting | 466 | Incyte Corporation | Dec 2025 |
| NCT07023627 | MAESTRA 1 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | P2 | recruiting | 160 | Incyte Corporation | Nov 2025 |
| NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment | P1 | not yet recruiting | 16 | Incyte Corporation | May 2026 | |
| NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease | P1 | not yet recruiting | 16 | Incyte Corporation | May 2026 | |
| NCT06909162 | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants | P1 | recruiting | 51 | Incyte Corporation | May 2025 | |
| NCT07218744 | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants | P1 | completed | 9 | Incyte Corporation | Nov 2025 |
INCB123667 clinical trials: frequently asked questions
- How many INCB123667 clinical trials are there?
- 6 INCB123667 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 1 is marked completed.
- Are INCB123667 clinical trials recruiting in 2026?
- Yes — 3 INCB123667 trials are actively recruiting in 2026, with 35 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is INCB123667 being studied for?
- INCB123667 is being studied for Healthy Participants, Ovarian Cancer, Hepatic Insufficiency, Liver Diseases, Renal Impairment. The trials are grouped by indication on this page.
- What phase is INCB123667 in?
- INCB123667 clinical trials span 1 Phase 3, 1 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors INCB123667 clinical trials?
- The lead sponsor across the most INCB123667 trials is Incyte Corporation. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming INCB123667as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: